🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Milestone Scientific Inc. MLSS PHARMA

Healthcare · Medical Instruments & Supplies · United States
https://www.milestonescientific.com
Company Profile ↓
$0.44
-26.67% 1Y
Mkt Cap$39.87M
P/E-8.80
P/B10.45
52W High$0.65
52W Low$0.25
Book Value$0.04
EPS (TTM)$-0.05

Company Overview

Milestone Scientific Inc., a biomedical technology company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical and dental use in the United States, China, and internationally. It operates through Dental and Medical segments. The company provides the Wand, a single use disposable handpiece device for dental procedures that require local anesthetic under the CompuDent and STA Single Tooth Anesthesia System names. It also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, the company provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications. Further, it offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.18.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $8.97M (+4.0% YoY); net profit $-5.72M.
  • Trailing 12 Months Year-on-year growth — revenue +22.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR -0.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-0.55%
1 Year:22.30%

Stock Price Performance

1 Year:-26.67%
6 Months:+57.14%
3 Months:+15.79%
1 Month:-8.33%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 48% of range
$0.25 $0.65
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)43.77 · Neutral
Price Performance
1M-8.33%
3M+15.79%
6M+57.14%
1Y-26.67%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -0.5% CAGR over 5 years.
  • Trading 32.3% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-8.80
Industry PE
24.83
Forward P/E
-12.57
PEG Ratio
-
Book Value
$0.04
Price to Book
10.45
P/S
3.92
EV/EBITDA
-8.62
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-0.55%
Profit 5Y
-
Revenue (YoY)
22.30%
Earnings (YoY)
-

Profitability & Returns

ROCE
-
ROE
-121.67%
ROA
-31.28%
Profit Margin
-43.98%
Op Margin
-37.36%
Gross Margin
70.23%
EPS (Latest Qtr)
$-0.01
EPS (TTM)
$-0.05

Balance Sheet & Liquidity

Debt/Equity
0.18
Quick Ratio
0.71
Current Ratio
1.85
Debt
$615.70K
Total Assets
$7.96M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
16.01%
Chg in Prom Hold
-0.05%
FII / Inst Holding
5.30%
Chg in FII Hold
0.08%

Financial Snapshot

Enterprise Value
$39.87M
Total Revenue (TTM)
$9.42M
EBITDA
$-4.03M
Free Cash Flow
$981.64K
Operating Cash Flow
$-642.64K
Shares Outstanding
90.61M
Gross Margin
70.23%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 MLSS Milestone Scientific Inc. PHARMA 0.44 -8.80 $39.87M 0.00% - -121.67% -0.55% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2013Jun 2013Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue 2.49M--2.62M------------------------------------
Gross Profit 1.68M1.53M1.77M1.74M1.59M1.71M1.84M1.20M1.67M2.20M1.58M1.67M2.29M1.65M1.81M1.24M1.41M-120.20K1.30M1.51M1.38M1.28M112.05K836.49K1.80M1.37M1.36M1.68M680.65K1.45M1.89M1.89M1.50M1.68M1.41M1.84M1.65M1.62M1.64M1.56M
Operating Income 167.76K151.11K436.27K329.25K47.51K-162.21K-71.14K-1.41M-835.36K-943.39K-2.02M-1.57M-525.93K-1.55M-1.41M-2.00M-1.42M-4.55M-818.18K-1.11M-946.73K-1.61M-3.17M-1.48M-984.37K-2.87M-1.98M-1.91M-2.88M-2.01M-1.34M-2.28M-1.51M-1.47M-1.78M-1.47M-2.00M-1.48M-1.13M-828.08K
Net Income 150.75K74.01K218.52K194.83K-169.46K-358.49K-419.38K-2.07M-1.57M-750.06K-1.59M-1.70M-504.87K-1.48M-1.41M-1.87M-1.34M-4.39M-782.75K-1.04M-2.84M-1.60M-3.17M-1.49M-972.87K-2.68M-2.04M-1.90M-2.86M-1.97M-1.31M-2.22M-1.47M-1.44M223.64K-1.46M-1.99M-1.48M-1.15M-839.85K
Diluted EPS 0.010.000.010.01-0.01-0.02-0.02-0.09-0.07-0.03-0.06-0.06-0.02-0.05-0.04-0.06-0.04-0.12-0.02-0.02-0.06-0.03-0.06-0.02-0.01-0.04-0.03-0.03-0.04-0.03------0.02-0.02--0.01-0.01
R&D Expense 121.84K42.88K12.70K15.72K29.16K29.37K10.12K18.82K20.68K143.44K309.33K303.27K105.02K120.06K16.88K225.82K9.78K1.50K6.35K95.53K7.94K107.48K108.17K21.44K16.44K215.42K356.18K464.47K266.56K166.19K140.35K213.65K170.48K94.21K314.97K232.06K369.12K51.79K16.23K-

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 9.75M8.38M8.65M10.01M10.33M9.49M10.48M11.28M9.62M8.37M5.44M10.30M8.81M9.83M8.63M8.97M
Gross Profit 6.22M5.36M5.59M6.81M6.70M6.44M6.31M6.97M4.43M5.72M3.62M6.31M4.90M6.79M6.43M6.41M
Operating Income -700.84K-1.22M-520.35K1.09M-790.18K-3.06M-6.51M-5.23M-8.00M-4.00M-7.45M-7.38M-8.83M-7.11M-6.76M-5.70M
Net Income -614.51K-1.48M-870.31K1.46M-1.70M-5.47M-5.95M-5.19M-7.43M-7.52M-7.34M-6.82M-8.71M-6.93M-4.71M-5.72M
Diluted EPS ---0.050.08-0.08-0.26-0.22-0.16-0.21-0.16-0.12-0.10---0.06-0.07
R&D Expense 270.49K140.05K181.98K191.34K88.24K100.86K1.27M272.75K245.64K189.92K307.85K878.21K1.15M701.38K858.77K449.47K

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -6.61M6.99M5.66M8.06M17.48M12.81M14.18M15.63M6.40M6.56M19.57M19.81M13.70M11.37M9.80M7.81M
Total Equity 2.64M2.33M1.94M1.94M5.52M14.65M10.31M8.50M7.24M1.54M1.70M16.20M16.37M10.23M8.01M5.83M2.81M
Cash & Equivalents 1.03M627.08K96.32K165.25K1.15M10.37M4.19M3.60M2.64M743.43K1.52M14.22M14.76M8.72M2.98M3.26M1.11M
Total Liabilities ----2.54M2.49M-5.65M8.13M4.87M4.93M3.46M3.59M3.70M3.36M3.96M4.99M
Current Liabilities -3.39M4.61M3.27M2.54M2.44M3.64M5.65M6.73M4.87M4.93M2.88M3.10M3.30M3.08M3.74M4.13M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -293.78K-570.73K-49.72K1.26M---5.40M-1.23M-1.63M-1.78M-6.98M-4.03M-6.03M-5.33M-2.92M-2.92M
Investing Cash Flow -108.27K-39.03K-31.36K-561.39K--8.21K-199.18K-15.42K-9.92K-21.44K-15.19K-8.53K-2.97M2.97M-15.12K
Financing Cash Flow -79.00K150.00K284.60K--4.80M463.34K-250.00K2.56M19.71M4.59M-8.54K2.56M233.77K786.34K
Capital Expenditure -29.36K-7.47K-4.74K-5.54K-82.21K-67.58K-15.34K-6.01K-7.40K-9.92K-21.44K-15.19K-8.53K--10.12K-15.12K
Free Cash Flow -323.13K-578.20K-54.45K1.25M---5.41M-1.24M-1.64M-1.79M-7.01M-4.05M-6.04M--2.93M-2.93M

Ratios (Annual)

Figures in %.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 63.8%64.0%64.7%68.0%64.9%67.9%60.2%61.8%46.1%68.3%66.6%61.3%55.7%69.1%74.6%71.4%
Operating Margin % -7.2%-14.6%-6.0%10.9%-7.6%-32.2%-62.1%-46.4%-83.1%-47.8%-137.1%-71.6%-100.2%-72.3%-78.3%-63.5%
Net Margin % -6.3%-17.7%-10.1%14.6%-16.5%-57.6%-56.7%-46.0%-77.2%-89.8%-134.9%-66.2%-98.9%-70.5%-54.6%-63.8%
ROE % -26.3%-76.5%-44.9%26.5%-11.6%-53.0%-70.0%-71.6%-482.7%-443.7%-45.3%-41.7%-85.1%-86.5%-80.8%-203.4%
ROCE % -21.8%-51.3%-21.8%19.7%-5.3%-33.4%-76.3%-58.8%-523.4%-245.5%-44.6%-44.1%-84.9%-85.7%-111.6%-155.0%

Shareholding Pattern

Insiders
16.01%
Institutions
5.30%
Public Float
6.31%

Top Institutional Holders

#Holder% HeldSharesValue
1 Vanguard Capital Management LLC 2.29% 2.07M $844.82K
2 Geode Capital Management, LLC 0.71% 643.61K $262.27K
3 Vanguard Fiduciary Trust Co 0.51% 464.45K $189.26K
4 State Street Corporation 0.29% 264.88K $107.94K
5 NFSG Corp 0.16% 141.00K $57.46K
6 Northern Trust Corporation 0.15% 133.07K $54.22K
7 LPL Financial LLC 0.14% 124.94K $50.91K
8 Mariner, LLC 0.13% 121.75K $49.61K
9 Carnegie Investment Counsel 0.11% 100.17K $40.82K
10 World Investment Advisors 0.11% 104.00K $42.38K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MLSS

Google News ue, 08 Sep 2026

Milestone Scientific (NYSE: MLSS) opens path to raise up to $45M - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNamRDeHZldmNjSkN6NmRtWllFY3QycHE5cTdSczlfZ0VkdVl3OC1QcUJKUEZCeGFvN1dQcC1QV3RnaG5PTmNZQmhfVlVPUDBaTGhhSEUtVWdvQy14ZXpNWVJHWEY5c2M5aVBQZTFieUFma2VJcjJCbE8wOWVBWk5UdXkwS01FNUtDSWhMbm…

Google News hu, 13 Aug 2026

Earnings To Watch: Milestone Scientific Inc (MLSS) Q2 2026 -- GF Value Sees 13% Upside - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPRDRKbWlOUDRHNGcycVFnU1JXTGVuM2w3Y2h4UDZGc2N1dFlvUGtXbzBFeUQwYUk3bDBzbHdVX1VuNl9uQ0dkdG5mbVhIdTNNYTdqQ3BLal9fYlU4cEZnakZabTM2SklMdTRXV1NhVUo5RG5SUmJRTlE3RFZ1MVQ0TjQ1dFdpZWlNSEVJeX…

Google News Fri, 31 Jul 2026

Milestone Scientific Inc. (NYSE: MLSS) investors back higher share and equity plan limits - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNcEdNWHZ1X2RzSGRlMml4VkdsbzhJaWg2cGh0c25XZi1JUnJNT051X015UWZ4RFJUZGVTZEdWcWM1TmRDMDBwU3J4bk5COXl6UHVCcHZCNVlZOGF4UDNYNkhKaXdNRzBnUkp3aDQ0bzI0WF9JTmwyZ1R1WENMeTRxUlZHc080UGJ2SlZlem…

Google News Fri, 14 Aug 2026

Milestone Scientific Reports 231% Growth in Medical Revenue, Announces VA and DoD Distribution Agreement and Reaffirms 2026 Outlook - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxNUVVoWVlybmJCVC1pbG5HUDJEcjVfVGI1RVZNeWRjalhsV01JMnlBYmM1R0JKYWFmZTN3TE93MFhUbmhaeUhueFM1SF9EZVdWOC1hWTMtVklHRFh1NF9pQ0FrNDNYb0RWNzREZkJVOVpWazZncnBaSldDdk1xLUwxQ3VqSEFwaWprclEtMn…

Google News Mon, 17 Aug 2026

Benchmark reiterates Speculative Buy on Milestone Scientific stock - Investing.com

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxNeFpISVJpckUxdWx3VDVWa19DNW5nSWNUZE9XUlZyUjJ0dU43NEZsS2U4S2Zpdi1KMTVSMnlvT0VzXzVETHoxejl3SjRXdlc5TEtiX3ZvVEZnN0VTSVhZMjRReVB1VHRiUmJUSDh0NF8ycXBBdlJOcmhpUERhSy00a2Y1T1ZYTF9nZHRRck…

Google News Wed, 29 Jul 2026

Milestone Scientific directors elect conversion of remaining bridge notes pending $0.50 fair value - tradingview.com

<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxOLTRnUy1EQ3kxQ1BvQmZ6eE9HYV9ZTXFjMm5RbnpqWTMtMUFnYldqUHBnYklPVTNkbkJjNmhXZDBRazBhSFB2UHo0dHlyMENJZEdjVkt3Q2NMU3BBN2djS2ZRY0FDMjZVYmRzU1RRQnozNDJaS28wODZKcGFhWlpvSmt6ZFl6azd5OFRiVT…

MLSS — Frequently Asked Questions

What is the current share price of Milestone Scientific Inc. (MLSS)?

As of 2026-09-19 21:16 PDT, Milestone Scientific Inc. (MLSS) trades at $0.44 on NYSE American. Its 52-week range is $0.25 to $0.65.

What is the market capitalisation of MLSS?

Milestone Scientific Inc. (MLSS) has a market capitalisation of $39.87M on NYSE American.

What is the P/E ratio of MLSS?

MLSS trades at a trailing price-to-earnings (P/E) ratio of -8.80. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 10.45.

What is the return on equity (ROE) of MLSS?

MLSS has a return on equity (ROE) of -121.67%.

Is MLSS a good stock to buy?

This page provides a data-driven analysis of Milestone Scientific Inc. (MLSS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space